FrancophonIA/ELRC3.0 huggingface dataset:
English: The bottle contains 240 ml of lamivudine solution (5 mg/ml).
Slovenian: Plastenka vsebuje 240 ml raztopine lamivudina (5 mg/ml).
English: Administration of trimethoprim/sulphamethoxazole 160 mg/800 mg increased lamivudine exposure by about 40 %.
Slovenian: Dajanje 160 mg/800 mg trimetoprima/sulfametoksazola je izpostavljenost lamivudinu zvečalo za 40 %.
English: The proportion of patients who had post-treatment ALT elevations in association with an increase in bilirubin levels was low and similar in patients receiving either lamivudine or placebo.
Slovenian: Odstotek bolnikov, ki so imeli zvišane vrednosti ALT po zdravljenju v povezavi s povečanjem nivoja bilirubina, je bil nizek in podoben pri bolnikih, ki so jemali ali lamivudin ali placebo.
English: - Week 260 4 negative positive < baseline positive > baseline
Slovenian: - 260. teden4 negativna pozitivna < izhodiščna vrednost pozitivna > izhodiščna vrednost
English: When possible, avoid chronic co-administration of Zeffix with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol, maltitol).
Slovenian: Če je mogoče, se izognite kronični sočasni uporabi zdravila Zeffix z zdravili, ki vsebujejo sorbitol ali druge osmotsko delujoče polialkohole oziroma monosahardine alkohole (npr. ksilitol, manitol, laktitol, maltitol).
English: However, the proportion of patients who had post-treatment elevations associated with bilirubin elevations was low and similar in both treatment arms (see Table 3 in section 5.1).
Slovenian: Toda delež bolnikov, ki se jim je po zdravljenju pojavilo zvišanje skupaj z zvišanjem bilirubina, je bil majhen in v obeh terapevtskih krakih podoben (glejte preglednico 3 v poglavju 5.1).
English: Sucrose 20 % w/v (4 g/20 ml) Methyl parahydroxybenzoate (E218) 1.5 mg/ml Propyl parahydroxybenzoate (E216) 0.18 mg/ml
Slovenian: saharoza 20 % w/v (4 g/20 ml) metilparahidroksibenzoat (E218) 1,5 mg/ml propilparahidroksibenzoat (E216) 0,18 mg/ml
English: These patients should be monitored for clinical, virological and serological parameters associated with hepatitis B, liver and renal function, and antiviral response during treatment (at least every month), and, if treatment is discontinued for any reason, for at least 6 months after treatment.
Slovenian: Pri takšnih bolnikih je treba nadzirati klinične, virološke in serološke parametre, povezane s hepatitisom B, jetrno in ledvično funkcijo ter protivirusni odgovor med zdravljenjem (vsaj mesečno), v primeru prekinitve zdravljenja iz kateregakoli razloga pa še vsaj 6 mesecev po zdravljenju.
English: If you have further questions, ask your doctor or pharmacist.
Slovenian: - Če imate dodatna vprašanja, se posvetujte s svojim zdravnikom ali farmacevtom.
English: In some patients the development of YMDD mutant HBV can lead to exacerbation of hepatitis, primarily detected by serum ALT elevations and re-emergence of HBV DNA (see section 4.2).
Slovenian: Pri nekaterih bolnikih lahko pojav YMDD mutanta HBV vodi do poslabšanja hepatitisa, kar se primarno zazna z zvišanjem serumske ALT in ponovnim pojavom HBV DNA (glejte poglavje 4.2).
English: In patients with compensated liver disease, these increases in serum ALT were generally not accompanied by an increase in serum bilirubin concentrations or signs of hepatic decompensation.
Slovenian: Pri bolnikih s kompenzirano boleznijo jeter zvišanja serumske ALT na splošno ni bilo pri povečanju koncentracije bilirubina v serumu ali znakih dekompenzacije jeter.
English: In an extended treatment study in Asian patients (NUCB3018) the HBeAg seroconversion rate and ALT normalisation rate at the end of the 5 year treatment period was 48 % (28/58) and 47 % (15/32), respectively.
Slovenian: V študiji podaljšanega zdravljenja pri bolnikih v Aziji (NUCB3018) je bil ob zaključku 5-letnega zdravljenja odstotek serokonverzije HBeAg 48 % (28/58), odstotek normalizacije ALT pa 47 %
English: Don't stop taking Zeffix without your doctor's advice, as there is a risk of your hepatitis getting worse.
Slovenian: Ne prenehajte z jemanjem zdravila Zeffix, ne da bi se prej posvetovali z zdravnikom; obstaja namreč tveganje za poslabšanje hepatitisa.
English: Lamivudine was not mutagenic in bacterial tests but, like many nucleoside analogues showed activity in an in vitro cytogenetic assay and the mouse lymphoma assay.
Slovenian: Z bakterijskimi testi mutagenost lamivudina ni bila dokazana, vendar je podobno kot mnogi nukleozidni analogi pokazal aktivnost v in vitro citogenetskem testu in testu na mišjem limfomu.
English: In patients who do not maintain a sustained serological response, consideration should be given to retreatment with either lamivudine or an alternative antiviral agent for resumption of clinical control of HBV.
Slovenian: Pri bolnikih, pri katerih se serološki odziv ni ohranil je potrebno razmisliti o ponovnem zdravljenju z lamivudinom ali uvedbi alternativnega protivirusnega zdravila, da bi se tako ponovno vzpostavila klinična nadzorovanost HBV.
English: If you forget to take Zeffix
Slovenian: Če ste pozabili vzeti zdravilo Zeffix
English: - Week 260 normal above normal < baseline above normal > baseline
Slovenian: - 260. teden normalna vrednost vrednost višja od normalne vrednosti < izhodiščna vrednost vrednost višja od normalne vrednosti > izhodiščna vrednost
English: The formation of further viral DNA is blocked by incorporation of lamivudine-TP into the chain and subsequent chain termination.
Slovenian: Lamivudin-TP blokira nadaljnje nastajanje virusne DNA tako, da se vključi v verigo in s tem povzroči terminacijo verige.
English: • breakdown of muscle tissue
Slovenian: • oslabelost mišičnega tkiva;
English: Cartons containing 240 ml lamivudine oral solution in an opaque, white, high-density polyethylene (HDPE) bottle with a polypropylene child resistant closure.
Slovenian: Škatle, ki vsebujejo 240 ml peroralne raztopine lamivudina v neprosojnih, belih plastenkah iz polietilena visoke gostote (HDPE), z za otroke varno zaporko iz polipropilena.
English: In patients followed for up to 16 weeks after discontinuation of treatment at one year, post-treatment ALT elevations were observed more frequently in patients who had received lamivudine than in patients who had received placebo.
Slovenian: Pri bolnikih, ki so bili po prekinitvi zdravljenja nadzirani do 16 tednov, je bilo zvišanje ALT eno leto po zdravljenju pogosteje opaženo pri bolnikih, ki so dobivali lamivudin, kot pa pri bolnikih, ki so dobivali placebo.
English: Reproductive studies in animals have not shown evidence of teratogenicity and showed no effect on male or female fertility.
Slovenian: Študije vpliva na sposobnost razmnoževanja pri živalih niso podale dokazov o teratogenosti, pokazale pa so, da ne vpliva na plodnost samcev ali samic.
English: The active ingredient in Zeffix is lamivudine.
Slovenian: Učinkovina v zdravilu Zeffix je lamivudin.
English: Don't take this medicine after the expiry date shown on the carton and blister.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in škatli.
English: Administration of lamivudine at very high dose levels in acute animal studies did not result in any organ toxicity.
Slovenian: Dajanje zelo velikih odmerkov lamivudina pri akutnih študijah na živalih ni vplivalo toksično na noben organ.
English: As anticipated due to the concomitant immunosuppression, the rate of emergence of YMDD mutant HBV after 52 weeks treatment was higher (36 % - 64 %) in the liver transplant population than in the immunocompetent CHB patients (14 % - 32 %).
Slovenian: Kot je bilo pričakovano zaradi spremljajoče imunosupresije, je bil odstotek pojavnosti YMDD mutanta HBV po 52 tednih zdravljenja večji (36 do 64 %) pri bolnikih s transplantacijo jeter kot pa pri imunokompetentnih bolnikih s CHB (14 do 32 %).
English: Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays low plasma protein binding to albumin.
Slovenian: Lamivudin kaže v območju terapevtskega odmerka linearno farmakokinetiko in nizko vezavo na plazemski protein albumin.
English: Data are limited on the use of lamivudine in HBeAg negative (pre-core mutant) patients and in those receiving concurrent immunosuppressive regimes, including cancer chemotherapy.
Slovenian: Imunosupresivno zdravljenje Podatki o uporabi lamivudina pri HBeAg negativnih bolnikih (okuženih s pre-core mutanto) in pri tistih, ki imajo predpisano sočasno imunosupresivno zdravljenje, vključno s kemoterapijo rakavih obolenj, so omejeni.
English: • emtricitabine, used to treat HIV or hepatitis B infection
Slovenian: • emtricitabin, ki se uporablja pri zdravljenju okužbe s HIV in pri okužbah s hepatitisom B,
English: Viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 with patients having continued improvement in virologic and biochemical responses.
Slovenian: Supresija virusa se je (nadaljevalna študija NUC20917) s kombiniranim zdravljenjem med drugim letom zdravljenja ohranila do 104. tedna in bolniki so še naprej imeli izboljšanje virološkega in biokemičnega odziva.
English: Maternal hepatitis B is not a contraindication to breast-feeding if the newborn is adequately managed for hepatitis B prevention at birth, and there is no evidence that the low concentration of lamivudine in human milk leads to adverse reactions in breastfed infants.
Slovenian: Hepatitis B pri materi ni kontraindikacija za dojenje, če je novorojenček ob rojstvu ustrezno voden glede preprečevanja hepatitisa B. Ni dokazov, da bi nizka koncentracija lamivudina v materinem mleku pri dojenčku povzročala neželene učinke.
English: For patients who are being treated with lamivudine and subsequently become pregnant consideration should be given to the possibility of a recurrence of hepatitis on discontinuation of lamivudine.
Slovenian: Pri bolnicah, ki se zdravijo z lamivudinom in potem zanosijo, je treba upoštevati možnost za ponovitev hepatitisa po prenehanju uporabe lamivudina.
English: Clear, colourless to pale yellow in colour.
Slovenian: peroralna raztopina Bistra, brezbarvna do bledo rumena.
English: This degree of viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 and most patients had improved markers of liver function and continued to derive clinical benefit.
Slovenian: Ta stopnja supresije virusa se je (nadaljevalna študija NUC20917) s kombiniranim zdravljenjem med drugim letom zdravljenja ohranila do 104. tedna; večina bolnikov je imela izboljšane označevalce delovanja jeter in jim je zdravljenje še naprej klinično koristilo.
English: Five percent (3/56) of patients without the YMDD mutant and 13 % (11/82) of patients with YMDD mutant showed worsening in liver inflammation compared to pre-treatment.
Slovenian: Pri petih odstotkih (3/56) bolnikov brez YMDD mutanta in 13 % (11/82) bolnikov z YMDD mutantom je prišlo do poslabšanja vnetnih sprememb v primerjavi s stanjem pred zdravljenjem.
English: The most common adverse reactions reported were malaise and fatigue, respiratory tract infections, throat and tonsil discomfort, headache, abdominal discomfort and pain, nausea, vomiting and diarrhoea.
Slovenian: Najpogosteje so poročali o naslednjih neželenih učinkih: slabem počutju in utrujenosti, infekcijah respiratornega trakta, neugodju v predelu grla in tonzil, glavobolu, neugodju in bolečinah v trebuhu, navzei, bruhanju in diareji.
English: Initial data indicate the efficacy of lamivudine in patients with HBeAg negative CHB is similar to patients with HBeAg positive CHB, with 71 % of patients having HBV DNA suppressed below the detection limit of the assay, 67 % ALT normalisation and 38 % with improvement in HAI after one year of treatment.
Slovenian: Prvotni podatki kažejo, da je učinkovitost lamivudina pri HBeAg negativnih bolnikih s CHB podobna tisti pri HBeAg pozitivnih bolnikih s CHB, s supresijo HBV DNA pod mejo dokazljivosti s testom pri 71 % bolnikov, normalizacijo ALT pri 67 % in izboljšanjem HAI pri 38 % bolnikov po enem letu zdravljenja.
English: compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and/or fibrosis.
Slovenian: • s kompenzirano jetrno boleznijo, z dokazano aktivno replikacijo virusa, s trajnim povečanjem vrednosti serumske alanin-aminotransferaze (ALT) in histološkimi dokazi aktivnega vnetja in/ali fibroze jeter.
English: There have been reports of mitochondrial dysfunction in infants exposed in utero and/or post-natally to nucleoside analogues (see section 4.4).
Slovenian: Opisani so primeri motenega delovanja mitohondrijev pri dojenčkih, ki so bili in utero in/ali postnatalno izpostavljeni nukleozidnim analogom (glejte poglavje 4.4).
English: Zeffix is an antiviral medicine that suppresses the hepatitis B virus and belongs to a group of medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Slovenian: Zdravilo Zeffix je protivirusno zdravilo, ki zavira virus hepatitisa B in spada v skupino zdravil, imenovanih nukleozidn zaviralci reverzne transkriptaze (NRTI).
English: • In patients with decompensated liver disease or cirrhosis and in liver transplant recipients, treatment cessation is not recommended (see section 5.1).
Slovenian: • Pri bolnikih z dekompenzirano jetrno boleznijo ali cirozo in pri bolnikih s presajenimi jetri prekinitev zdravljenja ni priporočljiva (glejte poglavje 5.1).
English: Zeffix can pass into breast-milk.
Slovenian: Zdravilo Zeffix lahko prehaja v materino mleko.
English: Muscle disorders, including myalgia and cramps*
Slovenian: Pogosti bolezni mišic, vključno z mialgijo in krči*
English: Zeffix is used to treat long term (chronic) hepatitis B infection in adults.
Slovenian: Zdravilo Zeffix se uporablja za zdravljenje dolgotrajne (kronične) okužbe s hepatitisom B pri odraslih.
English: Data obtained in patients with hepatic impairment, including those with end-stage liver disease awaiting transplant, show that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction.
Slovenian: Podatki, pridobljeni pri bolnikih z jetrno okvaro, tudi pri tistih s končnim stadijem jetrne bolezni, ki čakajo na transplantacijo, kažejo, da jetrna disfunkcija farmakokinetike lamivudina znatno ne prizadene.
English: Confirmed HBeAg seroconversion occurred in 47 % (118/252) of subjects treated with lamivudine and 93 % (320/345) of subjects receiving lamivudine became HBV DNA negative (VERSANT [version 1], bDNA assay, LLOD < 0.7 MEq/ml) during the study.
Slovenian: Potrjena serokonverzija HBeAg se je pojavila pri 47 % (118/252) oseb, zdravljenih z lamivudinom, 93 % (320/345) oseb, ki so prejemale lamivudin, pa je med študijo postalo HBV DNA negativnih (VERSANT [verzija 1], bDNA test, LLOD < 0,7 Meq/ml).
English: Limited data are available on the consequences of ingestion of acute overdoses in humans.
Slovenian: O posledicah zaužitja akutnih prevelikih odmerkov pri človeku so na voljo le omejeni podatki.
English: Don't take this medicine after the expiry date shown on the bottle and the carton.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu.
English: The main adverse events reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlipasemia).
Slovenian: Glavni opisani neželeni učinki so hematološke motnje (anemija, nevtropenija) in presnovne motnje (hiperlipazemija).
English: In elderly patients the pharmacokinetic profile of lamivudine suggests that normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of < 50 ml/min (see section 4.2).
Slovenian: Farmakokinetični profil lamivudina pri starejših bolnikih kaže, da pojemanje ledvične funkcije med normalnim staranjem nima klinično pomembnega učinka na izpostavljenost lamivudina, razen pri bolnikih, ki imajo očistek kreatinina < 50 ml/min (glejte poglavje 4.2).
English: Given the risk of YMDD mutant HBV, maintenance of lamivudine monotherapy is not appropriate in patients with detectable serum HBV DNA at or beyond 24 weeks of treatment (see section 4.4).
Slovenian: Glede na tveganje za YMDD mutant HBV vzdrževanje monoterapije z lamivudinom ni primerno za bolnike, ki imajo 24. teden zdravljenja ali pozneje v serumu zaznavno HBV DNA (glejte poglavje 4.4).
English: Check with your doctor if you think this applies to you.
Slovenian: Posvetujte se z zdravnikom, če mislite, da to velja za vas.
English: Laboratory parameters to be monitored should include (as a minimum) serum ALT, bilirubin, albumin, blood urea nitrogen, creatinine, and virological status: HBV antigen/antibody, and serum HBV DNA concentrations when possible.
Slovenian: Med laboratorijske parametre, ki jih je treba nadzirati, morajo biti vključeni (najmanj) serumski ALT, bilirubin, albumin, dušik sečnine v krvi, kreatinin in virološki status: HBV
English: A very common side effect (these may affect more than 1 in 10 people) which may show up in blood tests is:
Slovenian: Zelo pogost neželeni učinek (pojavi se lahko pri več kot 1 od 10 bolnikov), ki se lahko pokaže pri preiskavah krvi, je:
English: A side effect which may show up in blood tests is:
Slovenian: Neželeni učinek, ki se lahko pokaže pri preiskavah krvi, je:
English: In patients with decompensated liver disease, lamivudine should always be used in combination with a second agent, without cross-resistance to lamivudine, to reduce the risk of resistance and to achieve rapid viral suppression.
Slovenian: Pri bolnikih z dekompenzirano jetrno boleznijo, se mora lamivudin vedno uporabljati v kombinaciji z drugim zdravilom, ki nima navzkrižne odpornosti z lamivudinom, da se zmanjša tveganje za rezistenco ter da se doseže hitro zaustavitev virusne okužbe.
English: Reproductive studies in animals have shown no effect on male or female fertility (see section 5.3).
Slovenian: Študije vpliva na sposobnost razmnoževanja pri živalih ne kažejo učinkov na plodnost samic oziroma samcev (glejte poglavje 5.3).
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR TABLETS: 28 tablet box, 84 tablet box
Slovenian: PODATKI NA ZUNANJI OVOJNINI ZUNANJA OVOJNINA ZA TABLETE: škatla z 28 tabletami, škatla s 84 tabletami
English: Progression to cirrhosis occurred in 4/68 (6 %) patients with the YMDD mutant, whereas no patients without the mutant progressed to cirrhosis.
Slovenian: Do progresije v cirozo je prišlo pri 4/68 (6 %) bolnikov z YMDD mutantom in pri nobenem od bolnikov brez YMDD mutanta.
English: Moreover, Zeffix should not be taken with any other medicinal products containing lamivudine (see section 4.4).
Slovenian: Poleg tega, se Zeffix ne sme jemati z ostalimi zdravili, ki vsebujejo lamivudin (glejte poglavje 4.4).
English: Zeffix should not be taken with any other medicinal products containing lamivudine or medicinal products containing emtricitabine (see section 4.5).
Slovenian: Zdravila Zeffix se ne sme uporabljati z nobenim drugim zdravilom, ki vsebuje lamivudin, in tudi ne z zdravili, ki vsebujejo emtricitabin (glejte poglavje 4.5).
English: However, disease progression in YMDD subjects in the lamivudine group was lower than the disease progression in the placebo group (23/209, 11 % versus 38/214, 18 % respectively).
Slovenian: Napredovanje bolezni pri osebah z YMDD mutantom je bilo kljub temu manjše v skupini, ki je prejemala lamivudin v primerjavi z osebami v placebo skupini (23/209, 11 % v primerjavi z 38/214, 18 % v placebo skupini).
English: D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
Slovenian: D. POGOJI IN OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO
English: ALT 2 x baseline value; and bilirubin >2 x ULN and 2 x baseline value *Each patient may be represented in one or more category.
Slovenian: ALT ≥ 2 x osnovna vrednost; in bilirubin > 2 x ZMN in ≥ 2 x osnovna vrednost *vsak bolnik je lahko predstavljen v eni ali več kategorijah †Primerljivo stopnji 3 toksičnosti v skladu z modificiranimi kriteriji WHO
English: Zeffix is indicated for the treatment of chronic hepatitis B in adults with:
Slovenian: Zdravilo Zeffix je indicirano za zdravljenje kroničnega hepatitisa B pri odraslih:
English: If Zeffix is discontinued, patients should be periodically monitored both clinically and by assessment of serum liver function tests (ALT and bilirubin levels), for at least four months, and then as clinically indicated.
Slovenian: Če se zdravljenje z zdravilom Zeffix prekine, je bolnike treba periodično nadzirati tako klinično kot tudi z oceno serumskih testov jetrne funkcije (aktivnost ALT in koncentracija bilirubina) vsaj štiri mesece, nadalje pa, če je to klinično indicirano.
English: After two years of treatment in this study, ALT normalisation and undetectable HBV DNA occurred in 30/69 (43 %) and 32/68 (47 %) patients respectively and improvement in necroinflammatory score in 18/49 (37 %) patients.
Slovenian: Po dveh letih zdravljenja v tej študiji se je normalizacija ALT pojavila pri 30/69 (43 %) bolnikov, pri 32/68 (47 %) je bila HBV DNA nezaznavna, nekrozne in vnetne spremembe pa so se izboljšale pri 18/49 (37 %) bolnikov.
English: When lamivudine was discontinued, the majority of patients (70 %) had a return of viral replication.
Slovenian: Pri večini bolnikov (70 %) je po ukinitvi zdravljenja z lamivudinom ponovno prišlo do virusne replikacije.
English: • In patients with HBeAg positive chronic hepatitis B (CHB) without cirrhosis, treatment should be administered for at least 6-12 months after HBeAg seroconversion (HBeAg and HBV DNA loss with HBeAb detection) is confirmed, to limit the risk of virological relapse, or until HBsAg seroconversion or there is loss of efficacy (see section 4.4).
Slovenian: • Pri HBeAg pozitivnih bolnikih s kroničnim hepatitisom B (CHB) brez ciroze mora zdravljenje trajati še vsaj 6-12 mesecev po potrditvi serokonverzije HBeAg (izginotje HBeAg in HBV DNA ter detekcija HBeAb), da se omeji tveganje virusnega relapsa, ali do serokonverzije HBsAg ali pa se zmanjša učinkovitost (glejte poglavje 4.4).
English: Zeffix will not stop you passing hepatitis B infection on to other people.
Slovenian: Zdravilo Zeffix ne prepreči vašega prenašanja okužbe s hepatitisom B na druge osebe.
English: Diabetic patients should be advised that each dose of oral solution (100 mg = 20 ml) contains 4 g of sucrose.
Slovenian: Bolnikom s sladkorno boleznijo je treba razložiti, da vsak odmerek peroralne raztopine (100 mg = 20 ml) vsebuje 4 g saharoze.
English: In the controlled Phase III trials with no-active-treatment follow-up, the incidence of post-treatment ALT elevations (more than 3 times baseline) was higher in lamivudine-treated patients (21%) compared with those receiving placebo (8%).
Slovenian: ki niso obsegala spremljanja brez aktivnega zdravljenja, je bila incidenca zvišanj ALT (na več kot 3kratnik izhodiščne vrednosti) po zdravljenju večja pri bolnikih, zdravljenih z lamivudinom (21 %), kot pri bolnikih, ki so dobivali placebo (8 %).
English: Side effects that were commonly reported in Zeffix clinical trials were tiredness, respiratory tract infections, throat discomfort, headache, stomach discomfort and pain, nausea, vomiting and diarrhoea, increases in liver enzymes and enzymes produced in the muscles (see below).
Slovenian: Neželeni učinki, o katerih so pogosto poročali v kliničnih študijah z zdravilom Zeffix, so utrujenost, okužbe dihal, težave z grlom, glavobol, težave in bolečina v želodcu, siljenje na bruhanje, bruhanje in driska, zvišane vrednosti jetrnih encimov in encimov, ki so nastali v mišicah (glejte spodaj).
English: Where there is maternal transmission of HBV, despite adequate prophylaxis, consideration should be given to discontinuing breastfeeding to reduce the risk of the emergence of lamivudine resistant mutants in the infant.
Slovenian: V primeru prenosa HBV iz matere na otroka, kljub ustrezni profilaksi pride v poštev prenehanje dojenja, da bi pri dojenčku zmanjšali tveganje pojava proti lamivudinu odpornih mutantov.